

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form SC 13D/A  
December 10, 2004

OMB APPROVAL

-----  
OMB Number: 3235-0145  
Expires: December 31, 2005  
Estimated average burden  
hours per response....15

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(AMENDMENT NO. 5)\*  
-----

CARACO PHARMACEUTICAL LABORATORIES LTD

-----  
(Name of Issuer)

COMMON STOCK

-----  
(Title of Class of Securities)

14075T 10 7

-----  
(CUSIP Number)

Mr. Dilip S. Shanghvi  
Sun Pharmaceutical Industries Ltd.  
SPARC  
Akota Road, Akota  
Vadoadara 390 020 India  
With a Copy to:  
David B. Braun, Esq.  
Butzel Long  
150 West Jefferson, Suite 100  
Detroit, Michigan 48226  
313-983-7454

-----  
(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

December 1, 2004

-----  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. / /

NOTE: Schedules filed in paper format shall include a signed original and five

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form SC 13D/A

copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

SEC 1746 (11-03)

CUSIP No. 14075T 10 7

1. Names Of Reporting Persons.

I.R.S. Identification Nos. of Above Persons (Entities Only).

Sun Pharmaceutical Industries Limited

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Source of Funds (See Instructions)

WC

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) OR 2(e)

6. Citizenship or Place of Organization

India

7. Sole Voting Power

Number of

16,868,680

Shares

Beneficially

8. Shared Voting Power

0

Owned by Each

9. Sole Dispositive Power

Reporting

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form SC 13D/A

	16,868,680
Person	-----
	10. Shared Dispositive Power
With	0
-----	
11. Aggregate Amount Beneficially Owned by Each Reporting Person	
	16,868,680
-----	
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
-----	
13. Percent of Class Represented by Amount in Row (11)	
	64.18%
-----	
14. Type of Reporting Person (See Instructions)	
	CO
-----	
-----	
-----	
-----	
-----	

Item 1. Security and Issuer

This statement relates to the Common Stock, without par value (the "Shares"), of Caraco Pharmaceutical Laboratories Ltd., a Michigan corporation (the "Company"). The principal executive offices of the Company are located at 1150 Elijah McCoy Drive, Detroit, Michigan 48202.

Item 2. Identity and Background

(a) This statement is being filed pursuant to Rule 13d-(1)(f) promulgated under the Securities and Exchange Act of 1934, as amended (the "Act") by Sun Pharmaceutical Industries Limited, a corporation organized under the laws of India ("Sun" or the "Reporting Person"). Sun is referred to as a "Reporting Person."

(b) -- (c) Sun is a corporation organized under the laws of India. Sun is a specialty pharmaceutical company. Sun's business address is Acme Plaza, Andheri Kurla Road, Andheri (E) Mumbai 400059, India.

Pursuant to Instruction C to Schedule 13D under the Act, the directors and executive officers of Sun and their respective business addresses and present principal occupations are set forth below:

NAMES, BUSINESS ADDRESSES AND PRINCIPAL OCCUPATIONS OF THE DIRECTORS OF SUN

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form SC 13D/A

NAME OF THE DIRECTORS	ADDRESS
SHRI DILIP S. SHANGHVI	C/o Sun Pharmaceutical Industries Ltd Acme Plaza, Andheri Kurla Road, Andheri (East), MUMBAI -- 400 059.
SHRI SUDHIR V. VALIA	C/o Sun Pharmaceutical Industries Ltd Acme Plaza, Andheri Kurla Road, Andheri (East), MUMBAI -- 400 059.
SHRI SAILESH T. DESAI	C/o Sun Pharmaceutical Industries Ltd 402, 4th Floor, R. K. Centre, Fatehgunj Main Road, BARODA -- 390 002.
SHRI S. MOHANCHAND DADHA	C/o Sun Pharmaceutical Industries Ltd 10, Jeypore Nagar, CHENNAI - 600 086.
SHRI HASMUKH S. SHAH	C/o Sun Pharmaceutical Industries Ltd 402, 4th Floor, R. K. Centre, Fatehgunj Main Road, BARODA -- 390 002.
SHRI KEKI MINU MISTRY	C/o HDFC Limited Ramon House, 5th Floor, H. T. Parekh Marg, 169, Backbay Reclamation, Churchgate, Mumbai -- 400 020.
SHRI ASHWIN S. DANI	C/o Asian Paints (India) Ltd., 6-A, SHANTI NAGAR, SANTACRUZ (EAST), MUMBAI -- 400055

NAMES, BUSINESS ADDRESSES AND PRINCIPAL OCCUPATIONS OF THE EXECUTIVE OFFICERS OF SUN

Mr.Harin P. Mehta	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India
Mr.Rakesh Mehta	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India
Mr. Abhay Gandhi	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India
Mr. T.K.Roy	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India

## Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form SC 13D/A

Mr.Lokesh Sibbal	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India
Ms. Sharda Crishna	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India
Mr. Kamlesh M. Dudhara	SPARC, Akota Road, Akota, Baroda-390 020 Gujarat, India
Dr.T.Rajmanna	SPARC, Akota Road, Akota, Baroda-390 020 Gujarat, India
Dr. Amarjit Singh	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India
Mr.Kamlesh H Shah	Sun Pharmaceutical Industries Ltd., AcmePlaza,Andheri Kurla Road,Andheri (E) Mumbai -- 400 059 Maharashtra, India
Mr. Vipul Doshi	SPARC, Akota Road, Akota, Baroda-390 020 Gujarat, India

(d) To the best of its belief and based upon the information available to the Company, none of the entities or persons identified in this Item 2 has, during the last five years, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) To the best of its belief and based upon the information available to the Company, none of the entities or persons identified in this Item 2 has, during the last five years, been a party to a material

civil proceeding of a judicial or administrative body of competent jurisdiction and a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation relating to such laws.

(f) Sun is a corporation organized under the laws of India and each of its executive officers and directors named in this Item 2 are citizens of India.

### Item 3. Source and Amount of Funds or Other Considerations.

Sun used the proceeds of Foreign Currency Convertible Bonds issued by Sun to exercise options to acquire the Company's common stock. The Company and Sun Global Pharma, Inc., a wholly owned subsidiary of Sun, are also subject to an agreement (the "Agreement") effective November, 2002 pursuant to which, during a 5 year period, Sun Global is required to transfer and to sell to the Company the technology for up to 25 generic pharmaceutical products consisting

## Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form SC 13D/A

of ANDAs (abbreviated new drug applications) in exchange for 544,000 shares of Series B Convertible Preferred Stock for each product. So far, Sun Global has completed deliveries of 6 products and received 3,264,000 shares of Series B Convertible Preferred Stock pursuant to the Agreement.

On December 1, 2004, Sun exercised options as follows:

Options to purchase 110,000 shares of common stock at \$3.50 per share  
Options to purchase 100,000 shares of common stock at \$.88 per share  
Options to purchase 500,000 shares of common stock at \$1.50 per share  
Options to purchase 666,666 shares of common stock at \$2.63 per share  
Options to purchase 300,000 shares of common stock at \$1.31 per share  
Options to purchase 2,400 shares of common stock at \$.68 per share

In total Sun acquired 1,679,066 shares of common stock for a total purchase price of \$3,367,630.

### Item 4. Purpose of Transaction

Sun elected to exercise its options in order to provide the Company with additional working capital. In addition, some of the options exercised by Sun were expiring on January 1, 2005.

At this time, except as disclosed above, the Sun has no immediate plans or proposals which relate to or would result in:

- 1). the acquisition by any person of additional securities of the issuer, or the disposition of securities of the Company;
- 2). an extraordinary corporate transaction, such as a merger, reorganization or liquidation involving the Company;
- 3). a sale or transfer of a material amount of assets of the Company;
- 4). any change in the present board of directors or management of the Company, including any plans to change the number or term of directors except that the board may elect to fill an existing vacancy on the board;
- 5). any material change in the present capitalization or dividend policy of the Company;
- 6). any other material change in the Company's business or corporate structure;
- 7). changes in the Company's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person;
- 8). causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of registered national securities association;
- 9). the Shares becoming eligible for termination pursuant to Section

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form SC 13D/A

12(g)(4) of the Act; or

10). any action similar to those enumerated above.

Item 5. Interest in Securities of the Issuer

The following information is provided in response to Item 5 of Schedule 13D and is based on a total of 26,282,894 Shares outstanding (based on information from the Company as to the number of Shares outstanding as of December 1, 2004)

a-b).

Sole Voting Power

16,868,680\*

Shared Voting Power

0

Sole Dispositive Power

16,868,680\*

Shared Dispositive Power

0

Aggregate Amount Beneficially Owned

64.18%

\* Sun Pharma Global Inc., a wholly owned subsidiary of Sun also owns 3,264,000 shares of Series B. Preferred Stock which is convertible into Common Stock on a 1 for 1 basis after 3 years from the date of issue. Assuming conversion of the Preferred Stock into Common Stock and no other issuances of Common Stock by the Company, Sun owns the equivalent of 20,132,680 shares of Common Stock, approximately 68% of the outstanding Common Stock. The Series B Preferred Stock was acquired in four transactions in exchange for the delivery of new products on March 31, 2004, May 22, 2004, August 22, 2004 and August 27, 2004 at prices ranging from \$5.21 to \$8.57 per share.

d). No person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such Shares.

e). Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The Company and Sun Global are subject to a Products Agreement dated November 21, 2002 pursuant to which, Sun is required to transfer and sell to the Company the technology for up to 25 generic pharmaceutical products consisting of ANDAs (abbreviated new drug applications in exchange for 544,000 Shares for each product. So far, Sun Global has delivered 6 products and received 3,264,000 shares of Common Stock.

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form SC 13D/A

Item 7. Material to be Filed as Exhibits

None

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 10, 2004

Sun Pharmaceutical Industries Limited

By: /s/ Dilip S. Shanghvi

-----  
Dilip S. Shanghvi  
Chairman and Managing Director